Abstract 9053: Enhancing Neutrophil-Mediated DNase 1 Delivery to in vivo Thrombi via Pharmacological CXCR4 Inhibition
Circulation · 02.11.2026 · 154 (Suppl_1)
DOI: 10.1161/circ.154.suppl_1.9053 ↗Kurz gefasst
Fachartikel in der Zeitschrift Circulation, erschienen am 02.11.2026. Verfasst von Veronica Lisi und 9 weiteren Autor:innen.
Abstract (Originalsprache)
Venous thromboembolism is the 3rd leading cause of cardiovascular mortality in USA, affecting ~1 million people annually. While systemic thrombolysis with tPA effectively reduces thrombus burden, it carries a significant risk of major bleeding, including fatal intracerebral hemorrhage. Catheter-directed thrombolysis reduces tPA exposure but remains invasive and is still associated with bleeding complications. Neutrophil extracellular traps (NETs), composed of extracellular DNA and proteins, impair thrombus resolution, and increase resistance to thrombolysis. Importantly, NETs are not essential for hemostasis, making them an attractive therapeutic target. DNase 1 degrades extracellular DNA and, when combined with tPA, is more effective than tPA alone at dissolving human ex vivo thrombi. We previously demonstrated that DNase 1-loaded nanoparticles (DNP) can be internalized by neutrophils (Nϕ) which deliver DNP to thrombi in vitro . However, in our in vivo preliminary data ( Figures 1-2), ex vivo Nϕ localize to IVC thrombi but also show off-target accumulation in bone marrow (BM), lungs, and spleen, representing a potential barrier to clinical translation. Nϕ can be recruited to other organs through CXCR4, a cytokine’s receptor located on their surface which can bind to chemokines (e.g. CXCL12) present in organs such as spleen, BM, lungs, and liver. We hypothesize that pharmacological inhibition of CXCR4 with Plerixafor will reduce off-target organs Nϕ recruitment and alter their biodistribution, thereby improving the potential of Nϕ as cellular carriers for targeted delivery of DNP to in vivo venous thrombi. BM Nϕ were isolated from mice, labeled with Deep Red CellTracker™-DRN, and incubated with or without Plerixafor (10 μM, 30 min, 37°C). After washing, DRN ± Plerixafor treatment were intravenously injected into naïve mice and euthanized 1h after the injection. Organs were harvested and single-cell suspensions were prepared and stained with Nϕ markers antibodies (CD45 and Ly6G). The absolute number of injected DRN in each singles cell’s solution was quantified by flow cytometry and normalized on the total cells per organs. Preliminary flow cytometer analysis (N=3 biological replicates) showed that DRN treated with Plerixafor trended to alter DRN tissue distribution compared to untreated DRN. Plerixafor-treated DRN exhibited reduced accumulation in the BM, while splenic localization trended to increase. These preliminary findings indicate that inhibition of the CXCR4 can modulate Nϕ trafficking and reduce recruitment to off-target organs, supporting the development of Nϕ-mediated DNP target delivery strategies. Ongoing studies in the murine Venous Thrombosis (IVC stenosis) model will determine whether CXCR4 inhibition similarly alters ex vivo Nϕ biodistribution under pathological conditions and increase their accumulation within thrombi.
Zitieren
APA
Lisi, V., Barnett, E., Kim, S., Buechler, N., Burham, E., Pollard, R., Kim-Shapiro, D. B., Pinkerton, N., Asmis, R., & Maiocchi, S. (2026). Abstract 9053: Enhancing Neutrophil-Mediated DNase 1 Delivery to in vivo Thrombi via Pharmacological CXCR4 Inhibition. Circulation, 154(Suppl_1). https://doi.org/10.1161/circ.154.suppl_1.9053
Vancouver
Lisi V, Barnett E, Kim S, Buechler N, Burham E, Pollard R, et al. Abstract 9053: Enhancing Neutrophil-Mediated DNase 1 Delivery to in vivo Thrombi via Pharmacological CXCR4 Inhibition. Circulation. 2026;154(Suppl_1). doi:10.1161/circ.154.suppl_1.9053
BibTeX
@article{Lisi2026,
author = {Lisi, Veronica and Barnett, Emily and Kim, Suhon and Buechler, Nancy and Burham, Erica and Pollard, Racheal and Kim-Shapiro, Daniel B and Pinkerton, Nathalie and Asmis, Reto and Maiocchi, Sophie},
title = {Abstract 9053: Enhancing Neutrophil-Mediated DNase 1 Delivery to in vivo Thrombi via Pharmacological CXCR4 Inhibition},
journal = {Circulation},
year = {2026},
volume = {154},
number = {Suppl_1},
doi = {10.1161/circ.154.suppl_1.9053}
}
EUVIMED